Wells Fargo & Company MN Buys 7,961 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Wells Fargo & Company MN increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 63,237 shares of the specialty pharmaceutical company's stock after purchasing an additional 7,961 shares during the quarter. Wells Fargo & Company MN owned approximately 0.11% of Supernus Pharmaceuticals worth $2,287,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in SUPN. Vanguard Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after buying an additional 22,852 shares in the last quarter. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the period. American Century Companies Inc. increased its stake in shares of Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 5.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after purchasing an additional 40,968 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock worth $14,449,000 after purchasing an additional 27,134 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on SUPN. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN traded down $0.23 on Thursday, hitting $32.26. 78,425 shares of the stock traded hands, compared to its average volume of 492,878. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The company has a market capitalization of $1.80 billion, a PE ratio of 30.13 and a beta of 0.90. The business has a 50 day simple moving average of $31.86 and a 200 day simple moving average of $34.97.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.30% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.